Intraligmentary Dexamethasone in Lower First Molars With Irreversible Pulpitis and Apical Periodontits
Pulpitis - Irreversible
About this trial
This is an interventional treatment trial for Pulpitis - Irreversible focused on measuring " irreversible pulpitis with apical periodontitis"
Eligibility Criteria
Inclusion Criteria: Age between 20-45 years old. Systemically healthy patient (ASA I or II). Lower first molar with: Preoperative sharp pain. Slight widening in the periodontal ligament (PDL). Vital response of pulp tissue to cold pulp tester (ethyl chloride spray). Exclusion Criteria: Patients allergic to anesthetics, or dexamethasone (other corticosteroids). Pregnant or nursing females. Patients having significant systemic disorder (ASA III or IV). Hemostatic disorders or anti-coagulant therapy during the last month. Consumption of opioid or non-opioid analgesics or corticosteroids during the last 12 h before treatment. Retreatment cases.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Inferior alveolar nerve block
Inferior alveolar nerve block with intraligmentary dexamethasone
Buccal infiltratation with intraligmentary dexamethasone
Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine
Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine for inferior alveolar nerve block and 0.4 mL of 8 mg/ 2mLdexamethasone for intraligmentary injection
Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine for buccal infiltratation and 0.4 mL of 8 mg/ 2mLdexamethasone for intraligmentary injection